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Abstract Cancer-germline genes (CGGs) code for
immunogenic antigens that are present in various human
tumors and can be targeted by immunotherapy. Their
expression has been studied in a wide range of human
tumors in adults. We measured the expression of 12 CGGs
in pediatric brain tumors, to identify targets for therapeutic
cancer vaccines. Real Time PCR was used to quantify
the expression of genes MAGE-A1, MAGE-A2, MAGE-A3,
MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MAGE-
C2, NY-ESO-1 and GAGE-1,2,8 in 50 pediatric braintumors
of different histological subtypes. Protein expression was
examined with immunohistochemistry. Fifty-ﬁve percent of
the medulloblastomas (n = 11), 86% of the ependymomas
(n = 7),40%ofthechoroidplexus tumors (n = 5)and67%
of astrocytic tumors (n = 27) expressed one or more CGGs.
Immunohistochemical analysis conﬁrmed qPCR results.
With exception of a minority of tumors, the overall level of
CGG expression in pediatric brain tumors was low. We
observedahighexpressionofatleastoneCGGin32%ofthe
samples. CGG-encoded antigens are therefore suitable tar-
getsinaveryselectedgroupofpediatricpatientswithabrain
tumor. Interestingly, glioblastomas from adult patients
expressedCGGsmoreoftenandatsigniﬁcantlyhigherlevels
compared to pediatric glioblastomas. This observation is in
line with the notion that pediatric and adult glioblastomas
develop along different genetic pathways.
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Introduction
Despite major advances in the treatment of childhood
cancer, cancer remains a common cause of death for
children [1 year of age [1]. Twenty-two percent of all
pediatric cancers are CNS tumors. Pediatric patients with
relapsed cancers of the CNS have a poor prognosis, and
therefore novel therapies for these patients are urgently
needed. Immunotherapy against brain tumors presents
unique challenges since the brain is considered an immune
Electronic supplementary material The online version of this
article (doi:10.1007/s11060-008-9577-6) contains supplementary
material, which is available to authorized users.
J. F. M. Jacobs   P. M. Hoogerbrugge   C. E. Gidding  
I. J. M. de Vries
Department of Pediatric Oncology, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands
O. M. Grauer
Department of Neurology, University of Regensburg,
Regensburg, Germany
O. M. Grauer   M. W. M. M. van de Rakt  
C. G. Figdor   I. J. M. de Vries   G. J. Adema (&)
Department of Tumor Immunology, Nijmegen Centre
for Molecular Life Sciences/278 TIL, P.O. Box 9101, 6500 HB
Nijmegen, The Netherlands
e-mail: g.adema@ncmls.ru.nl
F. Brasseur
Ludwig Institute for Cancer Research, Brussels Branch, Belgium
P. Wesseling
Department of Pathology, Radboud University Nijmegen
Medical Centre, Nijmegen, The Netherlands
P. Wesseling
Department of Pathology, Canisius-Wilhelmina Hospital,
Nijmegen, The Netherlands
P. G. Coulie
Christian de Duve Institute of Cellular Pathology, Universite ´
Catholique de Louvain, Brussels, Belgium
123
J Neurooncol (2008) 88:273–280
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the immune cells have access to the brain in spite of the
blood-brain barrier [2, 3]. Within malignant brain tumors
the blood-brain barrier is generally considered non-func-
tional. Progress in our understanding of immune responses
to CNS tumors have already led to novel clinical applica-
tions [4, 5]. Most experience has been obtained with
immunotherapeutic trials with dendritic cell vaccinations,
as reviewed by De Vleeschouwer et al. [6].
Immunotherapy is an attractive therapeutic option for
pediatric cancer patients because of its mild toxicity, and
because the child’s immune system is more potent and
ﬂexible compared to adults [7, 8]. However, implementa-
tion of immunotherapy in pediatric oncology has been
hampered by the lack of known tumor-speciﬁc antigens on
pediatric tumors.
Cancer-germline genes (CGGs) are expressed in a wide
range of human tumors and have a highly restricted
expression pattern in normal tissues [9, 10]. Antigens
encoded by CGGs have been extensively studied because of
their immunogenicity, tumor speciﬁcity, and their expres-
sion in a signiﬁcant proportion of adult tumors of various
histological types. Recently, we have shown that CGGs are
expressed in a large percentage of pediatric extra-cranial
solid tumors [11].
The aim of this study was to analyze CGG expression in
pediatric brain tumors. We report the results of a quanti-
tative real-time PCR analysis of the expression of 12 CGGs
in a panel of medulloblastomas, ependymomas, tumors of
the choroid plexus and astrocytic tumors.
Materials and methods
Tumor samples
Fresh-frozen tumor samples were available at the Depart-
ment of Pathology at the Radboud University Nijmegen
Medical Centre. All samples were from pediatric patients
(0–19-years-old) with a brain tumor diagnosed at the
Department of Pediatric Hemato-Oncology. Sections of the
frozen samples were stained with hematoxylin-eosin and
reviewed by the pathologist to verify tumor histology and
to evaluate the percentage of tumor cells. Samples were
only considered for study if the contents of tumor cells was
C80%.
RNA isolation and cDNA synthesis
Total RNA was isolated with TriZol reagent (Invitrogen,
Carlsbad, CA) and samples were treated with Deoxyribo-
nuclease I (Invitrogen) according to the manufacturer’s
protocol. To generate cDNA, 1 lg DNase-treated RNA
was reverse-transcribed with the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen) using oligo(dT)
primer and 50 units SuperScript II, according to the man-
ufacturer’s protocol. After ﬁrst-strand synthesis, samples
were diluted to a ﬁnal volume of 100 ll with water.
Conventional PCR
DuplexPCR ampliﬁcationofb-actinand GAPDHtranscripts
wascarriedoutina25-llreactionvolumecontaining2.5 llof
cDNA, 19 PCR Buffer (10 mM Tris–HCl pH 8.3, 50 mM
KCl, 1.5 mM MgCl2), 100 lM each dNTP, 0.4 lMe a c h
primer, and 0.625 units Taq DNA polymerase (TaKaRa,
Shiga, Japan). b-actin primers were as described [12]. GAP-
DH primers (originally available from Clontech, Palo Alto,
CA; kindly provided by Dr. B. Lethe ´)w e r e5 0-TgAAgg
TCggAgTCAACggATTTggT-30 (sense) and 50-CATgTggg
CCATgAggTCCACCAC-30 (antisense). Cycling was per-
formed in a TRIO-Thermoblock thermocycler (Biometra,
Go ¨ttingen,Germany)asfollows:94Cfor4 min,followedby
22cyclesof1 minat94C,1 minat65C,and1 minat72C.
Cyclingwas concludedwitha ﬁnalextensionstepat72Cfo r
15 min. PCR products were fractionated in 1.3% agarose gel
and visualized by ethidium bromide ﬂuorescence (b-actin,
626 bp; GAPDH, 983 bp). PCR ampliﬁcation of MAGE-A
transcripts was carried out with the primer pair designed by
Zammatteoet al.[13].Theseprimersderivefromaconsensus
nucleotidesequenceforthelastexonofthe12MAGE-Agenes
and give amplicons of *539 bp. PCR conditions were as
described above, except that PCR was performed for 30
cycles.
Quantitative real-time PCR
Expression of CGGs and of the reference gene b-actin, was
measured by quantitative PCR, based on TaqMan method-
ology, using the ABI PRISM 7700 Sequence Detection
System (Applied Biosystems, Warrington, UK). PCR reac-
tions were prepared with the qPCR Core Kit w/o dUTP
reagents (Eurogentec, Seraing, Belgium). Each reaction
(25 ll) contained 2.5 ll of cDNA, 19 PCR buffer contain-
ing the passive reference dye ROX, 5 mM MgCl2, 200 lM
each dNTP, 200 nM each primer, 100 nM probe, and 0.625
unitsDNA polymerase. Primers, probes andthermal cycling
conditions are given in Table 1 [14, 15]. Probes with 6FAM
and TAMRA labels were from Eurogentec. Probes with
6FAM and MGB-NFQ labels (for MAGE-A3, MAGE-A6
and MAGE-A12) were from Applied Biosystems. Quanti-
ﬁcation ofthe sampleswasachieved byextrapolationfroma
standard curve of serial dilution points of cDNA of the rel-
evantgene(SupplementaryFigure 1).Samplesandstandard
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123dilution points were assayed in duplicate or triplicate.
Standard calibration curves for b-actin and all CGGs were
linear over 4 (CGGs) or 5 (ß-actin) orders of magnitude and
had similar PCR efﬁciencies (slope from -3.45 to -3.77).
Differences in sensitivity between the assays for the various
genes (y-intercept from 38.7 to 41.6) were due in part to
differences in the actual cDNA copy number inthe standard
dilutions. cDNA copy numbers in the standards were veri-
ﬁedbytestingminimally12replicatesofthe1-copydilution
in each qPCR run. If needed, copy numbers of the test
sampleswerecorrectedbyafactorcalculatedonthebasisof
theresultsforthe1-copydilution.Normalizationofsamples
wasachievedbydividingthecopynumberofCGGbythatof
the reference gene, b-actin.
Immunohistochemistry
Immunochemistry was performed on 4 lm tissue sections
offormalin-ﬁxedparafﬁn-embeddedtissue blocks.Sections
were heated for 20 min in citrate buffer (10 mM, pH 6.0)
for antigen retrieval. The following mouse IgG1 monoclo-
nal antibodies (mAb) were used: E978 (anti-NY-ESO-1)
[16](Zymed,SanFrancisco,CA),MA454(anti-MAGE-A1)
[17] (Zymed, San Francisco, CA), and 57B (anti-MAGE-
A4)[ 18, 19] (kindly provided by Dr. G.C. Spagnoli, Uni-
versity Hospital Basel, Switzerland). Testis tissue with
intact spermatogenesis was used as positive control. Tissue
sections were incubated with mAb diluted in PBA: E978
(2.5 lg/ml), MA454 (1 lg/ml), or 57B (5 lg/ml), or with
IgG1 negative control antibody, at room temperature for
1 h. Binding sites of primary antibodies were then detected
by a biotinylated horse-antimouse secondary reagent
(Vector Laboratories, Burlingame, CA) followed by an
avidin–biotin complex system (ABC Elite, Vector Labo-
ratories). Diaminobenzidine tetrachloride served as a
chromogen. Immunoreactivity was assessed blindly with
respect to the mAb used.
Statistical analysis
Normalized CGG values are presented as means ± stan-
dard deviation (SD). The SD of the normalized CGG
values was calculated from the SD of the CGG and the
b-actin values using the following formula: CV = SQRT
[CV
2
b-actin + CVCGG
2 ], where CV = SD/mean value (as
described in the Sequence Detection System User Bulletin
2, 1997, Applied Biosystems). Differences in mRNA
expression levels between pediatric and adult glioblasto-
mas are calculated with the Spearman rank correlation. All
statistical tests were two-sided, signiﬁcance was deter-
mined as P\0.05.
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123Results
Study population
We analyzed cancer-germline gene (CGG) expression in
50 fresh-frozen tumors by reverse transcription and poly-
merase chain reaction (PCR) ampliﬁcation. All samples
were histologically proven brain tumors from pediatric
patients, B19-years old at the time of tumor resection and
classiﬁed according to the WHO 2007 classiﬁcation [20]
(Table 2). An extra-cohort of nine glioblastoma samples
from adult patients was also analyzed, for comparison to
pediatric glioblastoma. Integrity of cDNA samples was
veriﬁed by conventional, 22-cycle PCR ampliﬁcation of a
626 bp b-actin and a 983 bp GAPDH product (data not
shown). Samples were subjected to conventional PCR
ampliﬁcation with consensus primers for the 12 genes of
the MAGE-A family. Twenty-seven samples were positive,
indicating that, depending on the tumor type, 33–64% of
the investigated pediatric tumors expressed at least one
MAGE-A gene (Table 2).
CGG expression in pediatric brain tumors
The 27 MAGE-A-positive samples were subsequently ana-
lyzed by quantitative real-time PCR (qPCR), using the
TaqMan methodology, to measure the expression of the
individual MAGE genes, MAGE-A1, A2, A3, A4, A6, A10,
and A12. In addition, all 50 samples were tested by qPCR
for expression of genes MAGE-C2, NY-ESO-1 and GAGE-
1,2,8 (Table 2). CGG expression levels were normalized to
those of the b-actin gene (Fig. 1).
Medulloblastoma. Six of the 11 medulloblastoma
tumors expressed at least 1 of the 10 CGGs that were
analyzed. The expression of CGGs in medulloblastomas
was highly clustered (Table 3). One sample expressed high
levels (CGG/ß-actin ratios[10
-2) of 6 CGG genes. The
other medulloblastoma samples only sporadically expres-
sed CGGs, with CGG/ß-actin ratios above 10
-4.
Ependymoma. Six out of seven ependymoma samples
expressedatleast1CGG.Noneexpressedmorethan3.Here
the expression was therefore not clustered. Most positive
samples expressed NY-ESO-1 and/or GAGE-1,2,8. The
overall levels of CGG expression in ependymoma samples
were low, with CGG/b-actin ratios below 1 9 10
-3.
Choroid plexus tumor. Of the ﬁve choroid plexus tumors
analyzed, three showed no detectable CGG expression.
Samples #1 and #2 expressed at least three CGGs. Only in
one sample the CGG/b-actin ratio exceeded 1 9 10
-3.
Pilocytic astrocytoma. Nine out of 14 pilocytic astrocy-
tomas expressed at least one CGG. The overall expression
was low, one low pilocytic astrocytoma had a CGG/b-actin
ratio[1 9 10
-4.
Diffuse astrocytoma. Two out of three diffuse astrocy-
tomas expressed at least one CGG. The overall expression
level of CGGs on diffuse astrocytomas was low.
High grade astrocytoma. Eight out of 10 anaplastic
astrocytomas and glioblastomas expressed at least one
CGG. CGG/b-actin ratio in high grade astrocytomas did
not exceed 1 9 10
-3.
CGG expression in pediatric versus adult glioblastomas
The relatively low expression of MAGE genes in high grade
astrocytomas was unexpected since MAGE expression has
been reportedinalmostall adultglioblastomas[21].Inthese
studiesdifferentmethodswereused,immunohistochemistry
[21–24] and conventional, non-quantitative PCR [22–24].
Therefore we decided to select nine new adult glioblastoma
samples for MAGE qPCR analysis. All samples expressed at
least ﬁve MAGE-A genes at high levels. The difference
between the levels of MAGE-A genes expression in pedi-
atric versus adult glioblastomas is shown in Fig. 2
(P = 6.1 9 10
-6).
Table 2 Study group
Tumor type
a Number of patients Average age (range) % of MAGE-A-positive tumors
b
Medulloblastoma 11 12 years (4–19) 55
Ependymoma 7 7 years (1–12) 43
Choroid plexus tumor 5 4 years (1–10) 40
Pilocytic astrocytoma (WHO grade I) 14 6 years (3–15) 64
Diffuse astrocytoma (WHO grade II) 3 10 years (5–18) 33
Anaplastic astrocytoma (WHO grade III) 5 13 years (7–19) 60
Glioblastoma (WHO grade IV) 5 13 years (3–19) 60
Glioblastoma (WHO grade IV)
c 9 59 years (31–74) 100
a According to WHO 2007 classiﬁcation [20]
b Gene expression was determined by conventional PCR with consensus primers for the 12 genes of the MAGE-A family
c An extra cohort of adult patients with glioblastomas was studied to compare to pediatric glioblastomas (Fig. 2)
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Fig. 1 Cancer-germline gene (CGG) expression in pediatric brain
tumors measured by reverse transcription and quantitative real-time
PCR. Each graph shows the results for one CGG in 50 different tumor
samples. Samples are arranged in the same order in all graphs. The
horizontal axis indicates the tumor type (Medullobl., medulloblas-
toma; Ependy., ependymoma; Plexus, plexus choroideus; Ast.,
astrocytic tumors grade I to IV). The bars represent normalized
CGG expression values (CGG/ß-actin ratios)
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Immunohistochemistry with monoclonal antibodies
(mAbs) E978 (anti-NY-ESO–1), MA454 (anti-MAGE-A1)
and 57B (anti-MAGE-A4) was performed on available
parafﬁn-embedded tissues. Sections from normal testis
tissue were used as positive controls. The intensity of the
stainings correlated well with the level of CGG expression,
as shown in Fig. 3a, b. The MAGE-A1, MAGE-A4 and
NY-ESO-1 proteins were distributed homogenously
throughout the tissues. However, a minority of the tissues
had a heterogeneous staining pattern such as the MAGE-
A4 expression in medulloblastoma sample #1 (Fig. 3c). No
staining could be observed for samples that scored either
negative or with CGG/b-actin ratios below 10
-4.
CGG expression and tumor stage
The number of patients in each speciﬁc group of tumors
was too small to try to establish a correlation between CGG
expression and clinicopathological parameters. Stratiﬁca-
tion of the pediatric astrocytic tumors in pilocytic
astrocytoma (grade I), diffuse astrocytoma (grade II) and
high grade anaplastic astrocytomas and glioblastomas
(grade III and IV, respectively), revealed that the level of
CGG expression was not signiﬁcantly different between
groups. These data suggest that CGG expression in astro-
cytic tumors is not correlated with the grade of the
astrocytic tumor in pediatric patients.
Discussion
Antibodies and T cells can be identiﬁed that recognize
antigenic fragments derived from gene products expressed
by tumors [10, 25, 26]. A critical role for these anti-tumor
immune mechanisms in the eradication of cancer has been
demonstrated in numerous animal models and some clini-
cal trials [27, 28]. In the last decennia promising new
strategies for the development of antibodies and activated
T cells against tumor associated antigens have been
developed [29, 30]. In spite of the blood brain barrier, there
is accumulating evidence that even brain tumors can cause
immune activation and are amenable for immunotherapy
[2, 4, 31].
The identiﬁcation of immunogenic tumor associated
antigens is an essential step in the development of rational
cancer vaccines. The potential of CGGs as vaccine targets
has led to detailed studies of their expression in various
malignancies in adult patients [10, 32]. Previously, we
reportedontheexpressionofCGGsinpediatricextra-cranial
tumors[11].Herewereportthat,inourcohortof50pediatric
brain tumors, 68% expressed one or more CGGs. Immuno-
histochemical data correlated well with the qPCR results.
Apart from a few exceptions, the overall level of CGG
expressiononpediatricbraintumorsislow.Preliminarydata
Table 3 Clustered pattern of cancer-germline gene expression in medulloblastomas
Sample MAGEA1 MAGEA2 MAGEA3 MAGEA4 MAGEA6 MAGEA10 MAGEA12 MAGEC2 NY-ESO-1 GAGE1,2,8
1 ++ ++++ ++++ - ++++ ++++ ++++ - ++++ +
2 -+ + +++- + -- -
3 ----+- + + -- + +
4 ------ + -- -
5 ------ + -- -
6 ---+-- - -- -
7 ------ - -- -
8 ------ - -- -
9 ------ - -- -
10 ------ - -- -
11 ------ - -- -
The signs +, ++, +++, and ++++ represent CGG/ß-actin ratios ranging between 10
-5 and 10
-4,1 0
-4 and 10
-3,1 0
-3 and 10
-2, and[10
-2
(see Fig. 1). -, no CGG expression was detected
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Fig. 2 MAGE-A expression in pediatric and adult glioblastomas.
Normalized MAGE-A expression levels (MAGE-A/ß-actin ratios) of
seven MAGE-A genes are shown. Horizontal bars represent mean
relative MAGE expression. Pediatric glioblastomas (closed circles)
express signiﬁcantly lower levels of MAGE-A compared to adult
glioblastomas (open circles), P = 6.1 9 10
-6 calculated with Spear-
man rank correlation
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123from cytotoxicity assays indicated that glioblastoma cell
lines that express low levels of CGGs (CGG/b-actin
ratio\1 9 10
-4) are not speciﬁcally lysed by HLA-mat-
ched anti-MAGE A3 CTL cell lines (data not shown).
In contrast to the limited CGG expression found in pedi-
atricbraintumors,glioblastomasfromadultpatientsexpress
signiﬁcantly higher levels of CGGs (P\0,001). This ﬁnd-
ing is in line with reported differences between adult and
pediatric glioblastomas in p53 and EGFR expression [33,
34]. The differences in protein expression may be explained
by chromosomal aberrations and differences in microsatel-
lite stability between adult glioblastomas and pediatric
glioblastomas[35,36].ThesigniﬁcantdifferenceinMAGE-
A expression between adult and pediatric glioblastomas
supports the view that these tumors develop along distinct
genetic pathways.
In conclusion, we report limited CGG expression in
pediatric brain tumors. Only a small percentage of brain
tumors express high levels of CGGs. These data indicate
that CGGs can only be used as immune target in a selected
group of pediatric brain tumors.
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